

Day : Thursday  
Date: 3/20/2003  
Time: 17:28:13

**PALM INTRANET****Inventor Name Search Result**

Your Search was:

Last Name = HERMIDA OCHOA

First Name = ELIAS

Application#	Patent#	Status	Date Filed	Title	Inventor Name
10082743	Not Issued	030	02/22/2002	REGENERATION OF ARTICULAR CARTILAGE DAMAGED BY GRADE I AND II OSTEOARTHRITIS BY MEANS OF THE INTRAARTICULAR APPLICATION OF A MIXTURE OF SODIUM HYALURONATE AND CHONDROITIN SULFATE IN A GEL VEHICLE	HERMIDA OCHOA, ELIAS HUMBERTO

Inventor Search Completed: No Records to Display.

**Search Another:****Last Name**

HERMIDA OCHOA

**First Name**

ELIAS

**Inventor**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

L Number	Hits	Search Text	DB	Time stamp
1	3062	514/54	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:15
2	586	514/54 and hyaluron\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:15
3	106	(514/54 and hyaluron\$) and osteoarthri\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:16
4	97	((514/54 and hyaluron\$) and osteoarthri\$) and (cartilage or degenera\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:17
5	456	514/54 and chondroitin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:17
6	95	(514/54 and chondroitin) and osteoarthri\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:17
7	91	((514/54 and chondroitin) and osteoarthri\$) and (cartilage or degenera\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:18
8	77	(((514/54 and hyaluron\$) and osteoarthri\$) and (cartilage or degenera\$)) and (((514/54 and chondroitin) and osteoarthri\$) and (cartilage or degenera\$))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:18
9	11	(((514/54 and hyaluron\$) and osteoarthri\$) and (cartilage or degenera\$)) and (((514/54 and chondroitin) and osteoarthri\$) and (cartilage or degenera\$))) and viscoelas\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:20
10	889	514/825	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:20
12	23	(514/825 and chondroitin) and osteoarthri\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:23
13	19	((514/825 and chondroitin) and osteoarthri\$) and hyaluron\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:23
11	33	514/825 and chondroitin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:28
14	555	536/55.1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:28
15	0	536/55.1 and chondroitin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:28
16	113	536/55.1 and chondroitin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:29
17	33	(536/55.1 and chondroitin) and osteoarthri\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:36

18	220	536/55.1 and hyaluron\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:36
19	48	(536/55.1 and hyaluron\$) and osteoarthri\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:36
20	40	((536/55.1 and hyaluron\$) and osteoarthri\$) and cartilage	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:36
21	30	(((536/55.1 and hyaluron\$) and osteoarthri\$) and cartilage) and degenera\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:37
22	23	(((536/55.1 and hyaluron\$) and osteoarthri\$) and cartilage) and degenera\$) and ((536/55.1 and chondroitin) and osteoarthri\$)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 16:37

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1623kxg

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 46 Feb 24 TEMA now available on STN  
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 48 Feb 26 PCTFULL now contains images  
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 50 Mar 19 APOLLIT offering free connect time in April 2003

NEWS EXPRESS Jańuary 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:16:39 ON 20 MAR 2003

=> file reg  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY  
SESSION  
0.21  
0.21

FILE 'REGISTRY' ENTERED AT 11:16:58 ON 20 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAR 2003 HIGHEST RN 500101-42-8  
DICTIONARY FILE UPDATES: 19 MAR 2003 HIGHEST RN 500101-42-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

```
=> s 123352-36-3
L1           1 123352-36-3
              (123352-36-3/RN)
```

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	0.61

FILE 'HCAPLUS' ENTERED AT 11:17:23 ON 20 MAR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2003 VOL 138 ISS 12  
 FILE LAST UPDATED: 19 Mar 2003 (20030319/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1 and (osteoarthri? or arthrit?)  

    7 L1  

    4457 OSTEOARTHRI?  

    29172 ARTHRIT?  

L2          0 L1 AND (OSTEOARTHRI? OR ARTHRIT?)
```

```
=> s l1 and cartilage  

    7 L1  

    19263 CARTILAGE  

    870 CARTILAGES  

    19396 CARTILAGE  

          (CARTILAGE OR CARTILAGES)  

L3          0 L1 AND CARTILAGE
```

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.76	7.37

FILE 'REGISTRY' ENTERED AT 11:19:02 ON 20 MAR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAR 2003 HIGHEST RN 500101-42-8  
 DICTIONARY FILE UPDATES: 19 MAR 2003 HIGHEST RN 500101-42-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> S 123352-36-3/RN

L4 1 123352-36-3/RN

=> FIL MSDS-OHS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	7.77

FILE 'MSDS-OHS' ENTERED AT 11:19:04 ON 20 MAR 2003  
COPYRIGHT (C) 2003 MDL INFORMATION SYSTEMS (MDL)

FILE LAST RELOADED ON STN: Jan 28, 2003

The MSDS-OHS file includes the Material Safety Data Sheets, Summary Sheets, and Label Data for pure substances and mixtures.

ACS and CAS make no representation concerning the content and make no warranties of any kind regarding the accuracy or completeness of the database and specifically disclaim any liability for the content and information contained therein. Customer acknowledges that the database is the property of MDL Information Systems. For further notice of terms, conditions and restrictions, please type HELP USAGETERMS.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=> SET LIN 80

SET COMMAND COMPLETED

=> S L4 AND 1/RN.CNT

0 L4  
29082 1/RN.CNT  
L5 0 L4 AND 1/RN.CNT

=> D ALL 1-

L5 HAS NO ANSWERS

L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 123352-36-3/RN  
L5 0 SEA FILE=MSDS-OHS ABB=ON PLU=ON L4 AND 1/RN.CNT

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.30	9.07

FILE 'REGISTRY' ENTERED AT 11:20:09 ON 20 MAR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAR 2003 HIGHEST RN 500101-42-8  
 DICTIONARY FILE UPDATES: 19 MAR 2003 HIGHEST RN 500101-42-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
 SET COMMAND COMPLETED

=> D L4 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/ (N):y  
 THE ESTIMATED COST FOR THIS REQUEST IS 5.63 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
 RN 123352-36-3 REGISTRY  
 CN Chondroitin, hydrogen sulfate, sodium salt, mixt. with hyaluronic acid  
 sodium salt (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Hyaluronic acid, sodium salt, mixt. contg. (9CI)  
 OTHER NAMES:  
 CN Viscoat  
 MF H2 O4 S . x Na . x Unspecified . Unspecified  
 CI MXS  
 SR CA  
 LC STN Files: BIOBUSINESS, BIOSIS, CA, CAPLUS, CIN, MEDLINE, PHARMASEARCH,  
 PROMT, TOXCENTER, USPATFULL

CM 1

CRN 9067-32-7  
 CMF Unspecified  
 CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 9082-07-9

CMF H2 O4 S . x Na . x Unspecified


CM 3

CRN 9007-27-6  
CMF Unspecified  
CCI PMS, MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 4

CRN 7664-93-9  
CMF H2 O4 S



7 REFERENCES IN FILE CA (1962 TO DATE)  
7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

≡

=> file hcaplus  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY TOTAL  
SESSION  
FULL ESTIMATED COST 2.88 11.95

FILE 'HCAPLUS' ENTERED AT 11:21:58 ON 20 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2003 VOL 138 ISS 12  
FILE LAST UPDATED: 19 Mar 2003 (20030319/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

FULL ESTIMATED COST

ENTRY 2.25 SESSION 14.20

FILE 'APOLLIT' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CPLUS' ENTERED AT 11:22:15 ON 20 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 11:22:15 ON 20 MAR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'EMA' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 11:22:15 ON 20 MAR 2003  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 11:22:15 ON 20 MAR 2003  
Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 11:22:15 ON 20 MAR 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:22:15 ON 20 MAR 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIINDEX' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 11:22:15 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s arthriti?  
L6 225795 ARTHRITI?

=> s 16 and osteo  
L7 4097 L6 AND OSTEO

=> s 17 and cartilage  
L8 1349 L7 AND CARTILAGE

=> s 18 and (compos? or compoun?)  
10 FILES SEARCHED...  
18 FILES SEARCHED...  
L9 353 L8 AND (COMPOS? OR COMPOUN?)

=> s 19 and (hyaluron? or chondroitin)  
L10 79 L9 AND (HYALURON? OR CHONDROITIN)

=> s 110 and (treat? or method)  
10 FILES SEARCHED...  
18 FILES SEARCHED...  
L11 67 L10 AND (TREAT? OR METHOD)

=> s 111 and degener?  
L12 37 L11 AND DEGENER?

=> s 19 and viscoat  
L13 0 L9 AND VISCOAT

=> dis 112 1-37 bib abs

L12 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2003 ACS  
AN 1990:400283 CAPLUS  
DN 113:283  
TI Polysulfated glycosaminoglycan accelerates net synthesis of collagen and glycosaminoglycans by **arthritic** equine **cartilage** tissues and chondrocytes  
AU Glade, Michael J.  
CS Dep. Pharmacol., Northwestern Univ., Chicago, IL, 60611, USA  
SO American Journal of Veterinary Research (1990), 51(5), 779-85  
CODEN: AJVRAH; ISSN: 0002-9645  
DT Journal  
LA English  
AB Low mol. wt. polysulfated glycosaminoglycan (PSGAG) stimulated net collagen and glycoaminoglycan synthesis by normal and **arthritic** equine fetlock **cartilage** tissues in organ culture. **Arthritic** tissues were more sensitive to PSGAG stimulation. The rates of **cartilage**-specific type-II collagen and chondroitin sulfate-rich glycosaminoglycan synthesis by confluent chondrocyte cell cultures obtained from normal and **arthritic** equine **cartilage** tissues were increased by 25 and 50 mg of PSGAG/mL. Cells from **arthritic** **cartilage** were also more sensitive to the presence of PSGAG. In addn., concns. of PSGAG (25 and 50 mg/mL) approx. to those in synovial fluid after intra-articular injection of 250 mg of PSGAG inhibited the rate of collagen and glycosaminoglycan degrdn. in cell culture. These findings suggest that PSGAG may have a role in the heating of mild **cartilage** **degeneration** by encouraging the prodn. of replacement hyaline matrix materials, while delaying their subsequent degrdn. In contrast,

growth of cell cultures was inhibited by PSGAG, suggesting that these compds. may fail to stimulate chondrocyte replication, a prerequisite for tissue regeneration. Nonetheless, these observations provide direct evidence of a truly chondroprotective role for low mol. wt. PSGAG in the treatment of equine degenerative joint disease.

L12 ANSWER 2 OF 37 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 2003:110074 SCISEARCH  
GA The Genuine Article (R) Number: 638MW  
TI Alternative therapies for traditional disease states: Osteoarthritis  
AU Morelli V (Reprint); Naquin C; Weaver V  
CS Louisiana State Univ, Hlth Sci Ctr, Family Practice Residency Program, Med Ctr, 200 W Esplanade Ave, Suite 510, Kenner, LA 70065 USA (Reprint); Louisiana State Univ, Hlth Sci Ctr, Family Practice Residency Program, Med Ctr, Kenner, LA 70065 USA; Louisiana State Univ, Sch Med, Dept Family Med, Kenner, LA 70065 USA; Louisiana State Univ, Family Practice Ctr, Kenner, LA 70065 USA  
CYA USA  
SO AMERICAN FAMILY PHYSICIAN, (15 JAN 2003) Vol. 67, No. 2, pp. 339-344. Publisher: AMER ACAD FAMILY PHYSICIANS, 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA.  
ISSN: 0002-838X.  
DT Article; Journal  
LA English  
REC Reference Count: 41  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*  
AB Americans spend more on natural remedies for osteoarthritis than for any other medical condition. in treating osteoarthritis, glucosamine and chondroitin sulfate, two of the molecular building blocks found in articular cartilage, are the most commonly used alternative supplements. In randomized trials of variable quality, these compounds show efficacy in reducing symptoms, but neither has been shown to arrest progression of the disease or regenerate damaged cartilage. Although few clinical trials on S-adenosylmethionine exist, preliminary evidence indicates that it relieves pain to a degree similar, to that of nonsteroidal anti-inflammatory drugs but with fewer side effects. Clinical trials of dimethyl sulfoxide offer conflicting results. Neither ginger nor cetyl myristoleate has proven clinical usefulness.

L12 ANSWER 3 OF 37 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 2001:221601 SCISEARCH  
GA The Genuine Article (R) Number: 407CF  
TI Effect of pre-loading oral glucosamine HCl/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats  
AU Beren J; Hill S L; Diener-West M; Rose N R (Reprint)  
CS Johns Hopkins Univ, Sch Med, Dept Pathol, 659 Ross Res Bldg, 720 Rutland Ave, Baltimore, MD 21205 USA (Reprint); Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Biostat, Baltimore, MD 21205 USA  
CYA USA  
SO EXPERIMENTAL BIOLOGY AND MEDICINE, (FEB 2001) Vol. 226, No. 2, pp. 144-151.  
Publisher: SOC EXPERIMENTAL BIOLOGY MEDICINE, 195 WEST SPRING VALLEY AVE, MAYWOOD, NJ 07607-1727 USA.  
ISSN: 0037-9727.  
DT Article; Journal  
LA English  
REC Reference Count: 40  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*  
AB The therapeutic effect of a nutritional supplement consisting of a

combination of glucosamine hydrochloride (FCHG49), purified sodium **chondroitin** sulfate (TRH122), and manganese ascorbate (GCM) (3) was investigated in the rat model of collagen-induced autoimmune **arthritis** (CIA). The GCM **compound** was mixed with a palatable nutritional paste (Nutri-cal(R) [NC]). Oral administration of the NC/GCM **compound** was initiated in 26 rats 10 days before immunization and continued until the day of sacrifice. One group of 12 control rats was given no oral agents; a second group of 12 control rats received NC only. Evaluations included **arthritis** index (AI) scoring by three independent evaluators, histologic index (Hr) scoring of lesions, T-cell proliferation, and serological studies for antibody classes and sub-classes. Both the AI and HI criteria showed a statistically significant reduction in the prevalence of CIA in rats pretreated with the NC/GCM (54%) compared to the combined control groups (96%, chi (2) analysis P = 0.001). Rats fed the NC/GCM also exhibited a significant decrease in the severity of autoimmune **arthritis** in both the AI and HI compared to control Group 2 (immunized-NC) (chi (2) analysis P < 0.05). Histological studies verified the decreased incidence of **arthritis** in the NC/GCM group compared to control Group 2.

GCM **treatment** failed to alter T-cell proliferation and antibody production to bovine type-I collagen, indicating that its effects are not due to alteration of the antigen-specific immune response.

L12 ANSWER 4 OF 37 SCISEARCH COPYRIGHT 2003 ISI (R)  
AN 1998:851457 SCISEARCH  
GA The Genuine Article (R) Number: 135BZ  
TI Exercise protects against articular **cartilage** **degeneration** in the hamster  
AU Otterness I G (Reprint); Eskra J D; Blivin M L; Shay A K; Pelletier J P; Milici A J  
CS PFIZER INC, CENT RES, DEPT RAIID, BOX 338, GROTON, CT 06340 (Reprint); UNIV MONTREAL, NOTRE DAME HOSP, MONTREAL, PQ H3C 3J7, CANADA  
CYA USA; CANADA  
SO ARTHRITIS AND RHEUMATISM, (NOV 1998) Vol. 41, No. 11, pp. 2068-2076.  
Publisher: LIPPINCOTT-RAVEN PUBL, 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106.

ISSN: 0004-3591.

DT Article; Journal

FS LIFE; CLIN

LA English

REC Reference Count: 48

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Objective. It has been reported that osteoarthritis can occur in hamsters. The present study was undertaken to determine the effects of exercise on the **composition** of articular **cartilage** and synovial fluid and on the development of **cartilage** **degeneration** in these animals.

**Methods.** Young (2.5-month-old) group-housed hamsters were compared with 5.5-month-old hamsters that had undergone 3 months of daily wheel running exercise (6-12 km/day) or 3 months of sedentary, individually housed living. The condition of the femoral condyles was determined by scanning electron microscopy in 12 exercising hamsters, 12 sedentary hamsters, and 6 of the young controls. The content of proteoglycan, **hyaluronic** acid, hydroxyproline, and proline in synovial fluid and patellar **cartilage** was measured.

Results. By scanning electron microscopy, the femoral articular **cartilage** was smooth and undulating in young controls and older exercising hamsters. In contrast, the femoral condyles were fibrillated in all 12 of the sedentary hamsters. There was no difference in the patellar **cartilage** collagen content between the 3 groups, but proteoglycan content and synthesis were lower in the patellar **cartilage** of the sedentary group. Synovial fluid volume was also decreased in the sedentary group compared with the young controls or the older exercising hamsters.

Conclusion. A sedentary lifestyle in the hamster leads to a lower proteoglycan content in the **cartilage** and a lower synovial fluid volume. These changes are associated with **cartilage** fibrillation, pitting, and fissuring. Daily exercise prevents early **cartilage degeneration** and maintains normal articular **cartilage**.

L12 ANSWER 5 OF 37 USPATFULL  
AN 2003:65819 USPATFULL  
TI Device for regeneration of articular **cartilage** and other tissue  
IN Brekke, John H., Duluth, MN, UNITED STATES  
Bradica, Gino, Claremont, NH, UNITED STATES  
Goldman, Scott M., Paoli, PA, UNITED STATES  
PI US 2003045943 A1 20030306  
AI US 2002-199961 A1 20020719 (10)  
RLI Continuation-in-part of Ser. No. US 1998-206604, filed on 7 Dec 1998, GRANTED, Pat. No. US 6264701 Division of Ser. No. US 1994-242557, filed on 13 May 1994, GRANTED, Pat. No. US 5981825  
DT Utility  
FS APPLICATION  
LREP Alan D. Kamrath, Kensey Nash Corporation, 55 E. Uwchlan Avenue, Exton, PA, 19341  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1263  
AB An implantable device for facilitating the healing of voids in bone, **cartilage** and soft tissue is disclosed. A preferred embodiment includes a **cartilage** region comprising a polyelectrolytic complex joined with a subchondral bone region. The **cartilage** region, of this embodiment, enhances the environment for chondrocytes to grow articular **cartilage**; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

L12 ANSWER 6 OF 37 USPATFULL  
AN 2003:38104 USPATFULL  
TI VEGF fusion proteins  
IN Kovesdi, Imre, Rockville, MD, UNITED STATES  
Kessler, Paul D., Frederick, MD, UNITED STATES  
PA GenVec, Inc., Gaithersburg, MD, UNITED STATES, 20878 (U.S. corporation)  
PI US 2003027751 A1 20030206  
AI US 2001-832355 A1 20010410 (9)  
DT Utility  
FS APPLICATION  
LREP LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780  
CLMN Number of Claims: 46  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 7034

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, **methods**

of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 37 USPATFULL  
AN 2003:37603 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)  
PI US 2003027248 A1 20030206  
AI US 2001-924340 A1 20010806 (9)  
PRAI US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 25650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 37 USPATFULL  
AN 2003:37516 USPATFULL  
TI Human cDNAs and proteins and uses thereof  
IN Bejanin, Stephane, Paris, FRANCE  
Tanaka, Hiroaki, Antony, FRANCE  
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)  
PI US 2003027161 A1 20030206  
AI US 2001-992600 A1 20011113 (9)  
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING  
PRAI WO 2001-IB1715 20010806  
US 2001-305456P 20010713 (60)  
US 2001-302277P 20010629 (60)  
US 2001-298698P 20010615 (60)  
US 2001-293574P 20010525 (60)  
DT Utility  
FS APPLICATION  
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Page(s)  
LN.CNT 25529

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in

screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening **compounds** that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 37 USPATFULL  
AN 2002:315279 USPATFULL  
TI Assessing the condition of a joint and assessing **cartilage** loss  
IN Lang, Philipp, Lexington, MA, UNITED STATES  
Steines, Daniel, Palo Alto, CA, UNITED STATES  
PI US 2002177770 A1 20021128  
AI US 2001-953373 A1 20010914 (9)  
PRAI US 2000-232637P 20000914 (60)  
US 2000-232639P 20000914 (60)  
DT Utility  
FS APPLICATION  
LREP COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO SQUARE, PALO ALTO, CA, 94306  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN 21 Drawing Page(s)  
LN.CNT 2925  
AB **Methods** are disclosed for assessing the condition of a **cartilage** in a joint and assessing **cartilage** loss, particularly in a human knee. The **methods** include converting an image such as an MRI to a three dimensional map of the **cartilage**. The **cartilage** map can be correlated to a movement pattern of the joint to assess the affect of movement on **cartilage** wear. Changes in the thickness of **cartilage** over time can be determined so that therapies can be provided. The amount of **cartilage** tissue that has been lost, for example as a result of **arthritis**, can be estimated.

L12 ANSWER 10 OF 37 USPATFULL  
AN 2002:273564 USPATFULL  
TI Transforming growth factor-beta-related molecules and uses thereof  
IN Jing, Shuqian, Thousand Oaks, CA, UNITED STATES  
PI US 2002151695 A1 20021017  
AI US 2001-995515 A1 20011128 (9)  
PRAI US 2000-253476P 20001128 (60)  
DT Utility  
FS APPLICATION  
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606  
CLMN Number of Claims: 57  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 4163

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides Transforming Growth Factor-Beta-Related (TGF-.beta.-R) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and **methods** for producing TGF-.beta.-R polypeptides. The invention further provides pharmaceutical **compositions** and **methods** for the diagnosis, **treatment**, amelioration, and/or prevention of diseases, disorders, and conditions associated with TGF-.beta.-R polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 37 USPATFULL

AN 2002:199250 USPATFULL  
TI Novel metalloproteases having thrombospondin domains and nucleic acid  
compositions encoding the same  
IN Heller, Renu Anand, Stanford, CA, UNITED STATES  
Zuo, Fengrong, San Jose, CA, UNITED STATES  
Klonowski, Paul, Cambridge, MA, UNITED STATES  
PI US 2002107361 A1 20020808  
AI US 2001-788043 A1 20010216 (9)  
PRAI US 2000-184152P 20000218 (60)  
DT Utility  
FS APPLICATION  
LREP Bret E. Field, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200  
Middlefield Road, Menlo Park, CA, 94025  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 2674

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel metalloproteases having thrombospondin domain(s) (MPTS proteins)  
and polypeptides related thereto, as well as nucleic acid  
compositions encoding the same, are provided. The subject  
polypeptide and nucleic acid compositions find use in a  
variety of applications, including diagnostic applications, therapeutic  
agent screening applications, as well as therapeutic applications for a  
variety of different conditions. Also provided are methods of  
treating disease conditions associated with aggrecanase  
activity, e.g. conditions characterized by the presence of aggrecan  
cleavage products, such as rheumatoid- and osteo-  
arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 37 USPATFULL  
AN 2002:198680 USPATFULL  
TI Extracellular matrix polynucleotides, polypeptides, and antibodies  
IN Fiscella, Michele, Bethesda, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002106780 A1 20020808  
AI US 2001-978249 A1 20011017 (9)  
RLI Continuation-in-part of Ser. No. WO 2001-US11643, filed on 11 Apr 2001,  
UNKNOWN  
PRAI US 2000-198123P 20000418 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 13488

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human extracellular matrix  
polypeptides and isolated nucleic acids containing the coding regions of  
the genes encoding such polypeptides. Also provided are vectors, host  
cells, antibodies, and recombinant methods for producing human  
extracellular matrix polypeptides. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing and  
treating disorders related to these novel human extracellular  
matrix polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 37 USPATFULL

AN 2002:171909 USPATFULL  
TI ASSAY FOR YKL-40 AS A MARKER FOR DEGRADATION OF MAMMALIAN CONNECTIVE  
TISSUE MATRICES  
IN PRICE, PAUL A., LA JOLLA, CA, UNITED STATES  
JOHANSEN, JULIA S., COPENHAGEN, DENMARK  
PI US 2002090658 A1 20020711  
AI US 1999-262213 A1 19990304 (9)  
RLI Continuation of Ser. No. US 1996-581527, filed on 17 Apr 1996, PATENTED  
Continuation of Ser. No. WO 1994-US7754, filed on 8 Jul 1994, UNKNOWN  
Continuation-in-part of Ser. No. US 1993-89989, filed on 9 Jul 1993,  
ABANDONED

DT Utility  
FS APPLICATION  
LREP LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501  
CLMN Number of Claims: 37  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Page(s)  
LN.CNT 1856

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is a **method** of identifying the presence of, and monitoring, a disease state in a mammal which is associated with degradation of connective tissue in the mammal. The **method** detects and determines whether diagnostically or prognostically significant levels of YKL-40 protein and/or YKL-40 peptide are present in a biological sample. The **method** can be used, for example, to identify the presence of inflammatory or **degenerative** joint disease or **degeneration** of connective tissue in organs. Serum YKL-40 levels as detected and quantified by the inventive **method** are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers. The figure shows the elution position of substantially pure serum YKL-40 on a gel filtration column.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 37 USPATFULL  
AN 2002:112873 USPATFULL  
TI Use of insulin for the **treatment** of cartilaginous disorders  
IN Filvaroff, Ellen H., San Francisco, CA, UNITED STATES  
Okumu, Franklin W., Oakland, CA, UNITED STATES  
PA GENENTECH, INC. (U.S. corporation)  
PI US 2002058614 A1 20020516  
AI US 2001-815229 A1 20010322 (9)  
PRAI US 2000-192103P 20000324 (60)  
DT Utility  
FS APPLICATION  
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080  
CLMN Number of Claims: 48  
ECL Exemplary Claim: 1  
DRWN 26 Drawing Page(s)  
LN.CNT 5581

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to **methods** for the **treatment** and repair of **cartilage**, including **cartilage** damaged by injury or cartilaginous disorders, including **arthritis**, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a **cartilage** agent (e.g., peptide growth factor, catabolism antagonist, **osteo**-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the **method** provides for the **treatment** and repair of **cartilage** damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the

method provides for the **treatment** and repair of  
**cartilage** damaged by injury or cartilagenous disorders  
comprising the administration of chondrocytes previously **treated**  
with an effective amount of insulin and/or insulin variant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 37 USPATFULL  
AN 2002:99407 USPATFULL  
TI Nucleic acids, proteins and antibodies  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002052308 A1 20020502  
AI US 2001-925301 A1 20010810 (9)  
RLI Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN  
PRAI US 1999-124270P 19990312 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 30577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and **treatment** of tissue specific disorders, particularly the presence of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic **methods** for producing the same. Also provided are diagnostic **methods** for diagnosing and **treating**, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic **methods** for **treating** such disorders. The invention further relates to screening **methods** for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to **methods** and/or **compositions** for inhibiting the production and/or function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 16 OF 37 USPATFULL  
AN 2002:78729 USPATFULL  
TI Nucleic acids, proteins, and antibodies  
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PI US 2002042386 A1 20020411  
AI US 2001-764870 A1 20010117 (9)  
PRAI US 2000-179065P 20000131 (60)  
US 2000-180628P 20000204 (60)  
US 2000-214886P 20000628 (60)  
US 2000-217487P 20000711 (60)  
US 2000-225758P 20000814 (60)  
US 2000-220963P 20000726 (60)  
US 2000-217496P 20000711 (60)  
US 2000-225447P 20000814 (60)  
US 2000-218290P 20000714 (60)  
US 2000-225757P 20000814 (60)  
US 2000-226868P 20000822 (60)

US 2000-216647P	20000707	(60)
US 2000-225267P	20000814	(60)
US 2000-216880P	20000707	(60)
US 2000-225270P	20000814	(60)
US 2000-251869P	20001208	(60)
US 2000-235834P	20000927	(60)
US 2000-234274P	20000921	(60)
US 2000-234223P	20000921	(60)
US 2000-228924P	20000830	(60)
US 2000-224518P	20000814	(60)
US 2000-236369P	20000929	(60)
US 2000-224519P	20000814	(60)
US 2000-220964P	20000726	(60)
US 2000-241809P	20001020	(60)
US 2000-249299P	20001117	(60)
US 2000-236327P	20000929	(60)
US 2000-241785P	20001020	(60)
US 2000-244617P	20001101	(60)
US 2000-225268P	20000814	(60)
US 2000-236368P	20000929	(60)
US 2000-251856P	20001208	(60)
US 2000-251868P	20001208	(60)
US 2000-229344P	20000901	(60)
US 2000-234997P	20000925	(60)
US 2000-229343P	20000901	(60)
US 2000-229345P	20000901	(60)
US 2000-229287P	20000901	(60)
US 2000-229513P	20000905	(60)
US 2000-231413P	20000908	(60)
US 2000-229509P	20000905	(60)
US 2000-236367P	20000929	(60)
US 2000-237039P	20001002	(60)
US 2000-237038P	20001002	(60)
US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 23133

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic **methods** for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic **methods** useful for diagnosing, **treating**, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening **methods** for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to **methods** and/or **compositions** for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 37 USPATFULL  
AN 2002:55324 USPATFULL  
TI Device for regeneration of articular **cartilage** and other tissue  
IN Brekke, John H., Duluth, MN, UNITED STATES  
Goldman, Scott M., Paoli, PA, UNITED STATES  
PI US 2002032488 A1 20020314  
AI US 2001-909027 A1 20010719 (9)  
RLI Continuation-in-part of Ser. No. US 1998-206604, filed on 7 Dec 1998, GRANTED, Pat. No. US 6264701 Division of Ser. No. US 1994-242557, filed on 13 May 1994, GRANTED, Pat. No. US 5981825  
DT Utility  
FS APPLICATION  
LREP Alan D. Kamrath, Kensey Nash Corporation, 55 E. Uwchlan Avenue, Exton, PA, 19341  
CLMN Number of Claims: 56  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1349  
AB An implantable device for facilitating the healing of voids in bone, **cartilage** and soft tissue is disclosed. A preferred embodiment includes a **cartilage** region comprising a polyelectrolytic complex joined with a subchondral bone region. The **cartilage** region, of this embodiment, enhances the environment for chondrocytes to grow articular **cartilage**; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between said regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

L12 ANSWER 18 OF 37 USPATFULL  
AN 2002:54632 USPATFULL  
TI ASSAY FOR YKL-40 AS A MARKER FOR DEGRADATION OF MAMMALIAN CONNECTIVE TISSUE MATRICES  
IN PRICE, PAUL A., LA JOLLA, CA, UNITED STATES  
JOHANSEN, JULIA S., COPENHAGEN, DENMARK  
PI US 2002031793 A1 20020314  
AI US 1998-215077 A1 19981218 (9)  
RLI Continuation of Ser. No. US 1996-581527, filed on 17 Apr 1996, GRANTED, Pat. No. US 5935798 A 371 of International Ser. No. WO 1994-US7754, filed on 8 Jul 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-89989, filed on 9 Jul 1993, ABANDONED  
DT Utility  
FS APPLICATION  
LREP TOM HUNTER, c/o SKJERVEN MORRILL MacPHERSON LLP, 25 METRO DRIVE, SUITE 700, SAN JOSE, CA, 95110  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Page(s)  
LN.CNT 1786  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention is a **method** of identifying the presence of, and monitoring, a disease state in a mammal which is associated with degradation of connective tissue in the mammal. The **method** detects and determines whether diagnostically or prognostically significant levels of YKL-40 protein and/or YKL-40 peptide are present in a biological sample. The **method** can be used, for example, to identify the presence of inflammatory joint disease or **degeneration** of connective tissue in organs. Serum YKL-40 levels as detected and quantified by the invention **method** are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 19 OF 37 USPATFULL  
AN 2002:37336 USPATFULL  
TI Transdermal delivery system  
IN Dransfield, Charles William, Lake Cathie, AUSTRALIA  
PI US 2002022052 A1 20020221  
AI US 2001-863764 A1 20010524 (9)  
PRAI AU 2000-8885 20000721  
AU 2000-6691 20000406  
DT Utility  
FS APPLICATION  
LREP Paul F. McQuade, GREENBERG TRAURIG, 12th FLOOR, 1750 TYSONS BLVD.,  
MCLEAN, VA, 22102  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 1341

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A transdermal or transepithelial **composition** and a  
**method** for making a transdermal or transepithelial  
**composition** substantially free of water comprising a  
biologically active agent in the form of microfined particles, sized  
less than 2 microns down to less than 0.1 microns, which by massage  
pressure are mechanically entrained within the interstices of the  
stratum corneum. Particles less than 0.5 microns do not require a  
carrier for entrainment. Delivery into mucosal epithelia is obtained by  
particles less than one micron with delivery increasing with decreasing  
particle size.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 20 OF 37 USPATFULL  
AN 2002:16578 USPATFULL  
TI **Composition and method for treating**  
inflammatory diseases  
IN Boone, Thomas C., Newbury Park, CA, UNITED STATES  
Hershenson, Susan, Newbury Park, CA, UNITED STATES  
Bevilacqua, Michael P., Boulder, CO, UNITED STATES  
Collins, David S., Fishers, IN, UNITED STATES  
PA Amgen Inc. (U.S. corporation)  
PI US 2002009454 A1 20020124  
AI US 2001-784623 A1 20010215 (9)  
RLI Division of Ser. No. US 1998-131247, filed on 7 Aug 1998, PENDING  
PRAI WO 1997-US2131 19970210  
US 1997-55185P 19970808 (60)  
DT Utility  
FS APPLICATION  
LREP Timothy J. Gaul, U.S. Patent Operations/TJG, Dept. 4300, M/S 27-4-A,  
AMGEN, INC., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 14 Drawing Page(s)  
LN.CNT 3525

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A protein which exhibits a therapeutic effect on inflammation and is  
useful for **treating** IL-1-mediated inflammatory diseases,  
particularly diseases of the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 21 OF 37 USPATFULL  
AN 2001:212429 USPATFULL

TI      **Compositions** useful in the **treatment** of diseases of connective tissues  
IN      Ekanayake, V.G. Sunetra, Halifax, Canada  
PI      US 2001044425      A1      20011122  
AI      US 2001-842742      A1      20010425 (9)  
PRAI     US 2000-200361P      20000428 (60)  
DT      Utility  
FS      APPLICATION  
LREP     Gerald T. Shekleton, Esq., Welsh & Katz, Ltd., 22nd Floor, 120 S. Riverside Plaza, Chicago, IL, 60606  
CLMN     Number of Claims: 25  
ECL     Exemplary Claim: 1  
DRWN    6 Drawing Page(s)  
LN.CNT 708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB      **Compositions** comprising ferrous ion and an ascorbate have a synergistic effect on **cartilage** development. Therapeutic **compositions** comprising ferrous ion and an ascorbate are therefore useful in the **treatment** of osteoarthritis. The addition of a glucosamine, such as glucosamine hydrochloride, to the **composition** has a further enhanced effect on **cartilage** production. Therapeutic **compositions** comprising ferrous ion, an ascorbate and a glucosamine derivative are even more useful in the **treatment** of osteoarthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12     ANSWER 22 OF 37 USPATFULL  
AN      2001:139603 USPATFULL  
TI      OSTEOGENIC DEVICES AND **METHODS** OF USE THEREOF FOR REPAIR OF ENDOCHONDRAL BONE, OSTEOCHONDRAL AND CHONDRAL DEFECTS  
IN      RUEGER, DAVID C., SOUTHBOROUGH, MA, United States  
       TUCKER, MARJORIE A., HOLLISTON, MA, United States  
       CHANG, AN-CHENG, WESTBOROUGH, MA, United States  
PI      US 2001016646      A1      20010823  
AI      US 1998-45331      A1      19980320 (9)  
DT      Utility  
FS      APPLICATION  
LREP     PATENT ADMINISTRATOR, TESTA HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET, BOSTON, MA, 02110  
CLMN     Number of Claims: 49  
ECL     Exemplary Claim: 1  
DRWN    2 Drawing Page(s)  
LN.CNT 5269

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB      Disclosed herein are improved osteogenic devices and **methods** of use thereof for repair of bone and **cartilage** defects. The devices and **methods** promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from **degenerative** diseases such as osteochondritis dessicans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12     ANSWER 23 OF 37 USPATFULL  
AN      2001:134213 USPATFULL  
TI      IMPROVED OSTEOGENIC DEVICES AND **METHODS** OF USE THEREOF FOR REPAIR OF ENDOCHONDRAL BONE AND OSTEOCHONDRAL DEFECTS  
IN      RUEGER, DAVID C, SOUTHBOROUGH, MA, United States  
       TUCKER, MARJORIE A, HOLLISTON, MA, United States  
PI      US 2001014662      A1      20010816

AI US 1997-822186 A1 19970320 (8)  
DT Utility  
FS APPLICATION  
LREP JAMES F. HALEY, FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY,  
100201104  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s) .  
LN.CNT 4425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are improved osteogenic devices and **methods** of use thereof for repair of bone and **cartilage** defects. The devices and **methods** promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from **degenerative** diseases such as osteochondritis dessicans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 24 OF 37 USPATFULL  
AN 2001:116310 USPATFULL  
TI Device and **methods** for in vivo culturing of diverse tissue cells  
IN Brekke, John H., Duluth, MN, United States  
PA Kensey Nash Corporation, Exton, PA, United States (U.S. corporation)  
PI US 6264701 B1 20010724  
AI US 1998-206604 19981207 (9)  
RLI Division of Ser. No. US 1994-242557, filed on 13 May 1994, now patented,  
Pat. No. US 5981825

DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Milano, Michael J.  
LREP Kamrath, Alan D.Rider Bennett Egan & Arundel LLP  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1148  
AB An anatomically specific, bioresorbable, implant device for facilitating the healing of voids in bone, **cartilage** and soft tissue is disclosed. A preferred embodiment of using the implant device for facilitating the healing of a human joint lesion includes a **cartilage** region invested with an alginate microstructure joined with a subchondral bone region invested with a **hyaluronan** microstructure. The alginate selectively dispersed in the **cartilage** region enhances the environment for chondrocytes to grow articular **cartilage**. The **hyaluronan** selectively dispersed in the subchondral bone region enhances the environment for mesenchymal cells which migrate into that region's macrostructure and which differentiate into osteoblasts. The microstructures can be invested at varying concentrations in the regions. A hydrophobic barrier, strategically positioned within the subchondral bone region macrostructure, shields the chondrocytes from the oxygenated blood in subchondral cancellous bone. In the preferred form, the **cartilage** region includes a tangential zone including a network of intercommunicating void spaces having a horizontal orientation and in communication with synovial fluid and includes a radial zone including multiple void spaces oriented in both horizontal and vertical planes and providing intercommunication between the tangential zone and the subchondral bone region.

L12 ANSWER 25 OF 37 USPATFULL  
AN 2000:77339 USPATFULL  
TI **Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury**  
IN Kuberasanpath, Thangavel, Medway, MA, United States  
Pang, Roy H. L., Etna, NH, United States  
Oppermann, Hermann, Medway, MA, United States  
Rueger, David C., Hopkinton, MA, United States  
Cohen, Charles M., Medway, MA, United States  
Smart, John E., Weston, MA, United States  
PA Creative BioMolecules, Inc., Boston, MA, United States (U.S. corporation)  
PI US 6077823 20000620  
AI US 1995-445467 19950522 (8)  
RLI Continuation of Ser. No. US 1993-165511, filed on 9 Dec 1993, now abandoned which is a continuation of Ser. No. US 1992-938336, filed on 28 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned And Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 30 Aug 1991, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Kemmerer, Elizabeth C.  
LREP Elrifi, Ivor R., Morency, MichelMintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 10 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 3794  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention is directed to **methods** and **compositions** for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The **methods** and **compositions** include administering a therapeutically effective concentration of a morphogen or morphogen-stimulating agent sufficient to alleviate immune cell-mediated tissue destruction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 26 OF 37 USPATFULL  
AN 2000:44203 USPATFULL  
TI **Compositions and therapeutic methods using morphogenic proteins and stimulatory factors**  
IN Lee, John C., San Antonio, TX, United States  
Yeh, Lee-Chuan C., San Antonio, TX, United States  
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)  
PI US 6048964 20000411  
AI US 1995-570752 19951212 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Nutter, Nathan M.  
LREP Fish & Neave, Haley, Jr., James F., Ruskin, Barbara A.  
CLMN Number of Claims: 21  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 3062  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides pharmaceutical **compositions** comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. **Methods** for improving the tissue inductive activity of a morphogenic protein in a

mammal using those **compositions** are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants.

**Methods** for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A **method** for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a **method** for promoting *in vivo* integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. **Methods of treating** tissue **degenerative** conditions in a mammal using the pharmaceutical **compositions** are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 27 OF 37 USPATFULL  
AN 1999:142232 USPATFULL  
TI Device and **methods** for *in vivo* culturing of diverse tissue cells  
IN Brekke, John H., Duluth, MN, United States  
PA THM Biomedical, Inc., Duluth, MN, United States (U.S. corporation)  
PI US 5981825 19991109  
AI US 1994-242557 19940513 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Clarke, Robert A.  
LREP Kamrath, Alan Peterson, Wicks, Nemer & Kamrath, P.A.  
CLMN Number of Claims: 42  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1250  
AB An anatomically specific, bioresorbable, implant device for facilitating the healing of voids in bone, **cartilage** and soft tissue is disclosed. A preferred embodiment of using the implant device for facilitating the healing of a human joint lesion includes a **cartilage** region invested with an alginate microstructure joined with a subchondral bone region invested with a **hyaluronan** microstructure. The alginate selectively dispersed in the **cartilage** region enhances the environment for chondrocytes to grow articular **cartilage**. The **hyaluronan** selectively dispersed in the subchondral bone region enhances the environment for mesenchymal cells which migrate into that region's macrostructure and which differentiate into osteoblasts. The microstructures can be invested at varying concentrations in the regions. A hydrophobic barrier, strategically positioned within the subchondral bone region macrostructure, shields the chondrocytes from the oxygenated blood in subchondral cancellous bone. In the preferred form, the **cartilage** region includes a tangential zone including a network of intercommunicating void spaces having a horizontal orientation and in communication with synovial fluid and includes a radial zone including multiple void spaces oriented in both horizontal and vertical planes and providing intercommunication between the tangential zone and the subchondral bone region.

L12 ANSWER 28 OF 37 USPATFULL  
AN 1999:106108 USPATFULL  
TI **Compositions** and therapeutic **methods** using morphogenic proteins and stimulatory factors  
IN Lee, John C., San Antonio, TX, United States  
Yeh, Lee-Chuan C., San Antonio, TX, United States  
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)

PI US 5948428 19990907  
AI US 1996-761468 19961206 (8)  
RLI Continuation-in-part of Ser. No. US 1995-570752, filed on 12 Dec 1995  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Azpuru, Carlos  
LREP Fish & Neave, Haley, James F., Ruskin, Barbara A.  
CLMN Number of Claims: 78  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 16 Drawing Page(s)  
LN.CNT 3767

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical **compositions** comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. **Methods** for improving the tissue inductive activity of a morphogenic protein in a mammal using those **compositions** are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. **Methods** for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A **method** for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a **method** for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. **Methods** of **treating** tissue **degenerative** conditions in a mammal using the pharmaceutical **compositions** are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 29 OF 37 USPATFULL  
AN 1999:72563 USPATFULL  
TI **Compositions** and therapeutic **methods** using morphogenic proteins and stimulatory factors  
IN Lee, John C., San Antonio, TX, United States  
Yeh, Lee-Chuan C., San Antonio, TX, United States  
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)  
PI US 5916870 19990629  
AI US 1998-158220 19980922 (9)  
RLI Division of Ser. No. US 1998-27873, filed on 23 Feb 1998 which is a division of Ser. No. US 1995-570752, filed on 12 Dec 1995  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Nutter, Nathan M.  
LREP Fish & Neave, Haley, James F., Ruskin, Barbara A.  
CLMN Number of Claims: 42  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 3176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical **compositions** comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. **Methods** for improving the tissue inductive activity of a morphogenic protein in a mammal using those **compositions** are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. **Methods** for inducing local tissue formation from a progenitor

cell in a mammal using those devices are also provided. A **method** for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a **method** for promoting *in vivo* integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. **Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions** are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 30 OF 37 USPATFULL  
AN 1999:952 USPATFULL  
TI Device and **methods** for *in vivo* culturing of diverse tissue cells  
IN Brekke, John H., Duluth, MN, United States  
Ringiesen, Timothy, Duluth, MN, United States  
PA THM Biomedical, Inc., Duluth, MN, United States (U.S. corporation)  
PI US 5855608 19990105  
AI US 1994-367510 19941230 (8)  
RLI Continuation-in-part of Ser. No. US 1994-242557, filed on 13 May 1994  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Clarke, Robert A.  
LREP Peterson, Wicks, Nemer & Kamrath, P.A.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 7 Drawing Page(s)  
LN.CNT 1257  
AB An anatomically specific, bioresorbable, implant device for facilitating the healing of voids in bone, **cartilage** and soft tissue is disclosed. A preferred embodiment of using the implant device for facilitating the healing of a human joint lesion includes a **cartilage** region invested with an alginate microstructure joined with a subchondral bone region invested with a **hyaluronan** microstructure. The alginate selectively dispersed in the **cartilage** region enhances the environment for chondrocytes to grow articular **cartilage**. The **hyaluronan** selectively dispersed in the subchondral bone region enhances the environment for mesenchymal cells which migrate into that region's macrostructure and which differentiate into osteoblasts. The microstructures can be invested at varying concentrations in the regions. A hydrophobic barrier, strategically positioned within the subchondral bone region macrostructure, shields the chondrocytes from the oxygenated blood in subchondral cancellous bone. In the preferred form, the **cartilage** region includes a tangential zone including a network of intercommunicating void spaces having a horizontal orientation and in communication with synovial fluid and includes a radial zone including multiple void spaces oriented in both horizontal and vertical planes and providing intercommunication between the tangential zone and the subchondral bone region.

L12 ANSWER 31 OF 37 USPATFULL  
AN 1998:162472 USPATFULL  
TI **Compositions** and therapeutic **methods** using morphogenic proteins and stimulatory factors  
IN Lee, John C., San Antonio, TX, United States  
Yeh, Lee-Chuan C., San Antonio, TX, United States  
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)  
PI US 5854207 19981229  
AI US 1998-27873 19980223  
RLI Division of Ser. No. US 1995-570752, filed on 12 Dec 1995

DT Utility  
FS Granted  
EXNAM Primary Examiner: Nutter, Nathan M.  
LREP Fish & Neave, Haley, Jr., James F., Ruskin, Barbara A.  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 3072

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical **compositions** comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. **Methods** for improving the tissue inductive activity of a morphogenic protein in a mammal using those **compositions** are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. **Methods** for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A **method** for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a **method** for promoting *in vivo* integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. **Methods** of **treating** tissue **degenerative** conditions in a mammal using the pharmaceutical **compositions** are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 32 OF 37 USPATFULL  
AN 97:83943 USPATFULL  
TI Anti-inflammatory compounds and compositions  
IN Cullis-Hill, David, Bondi Junction, Australia  
Ghosh, Peter, Fairlight, Australia  
PA Anthropharm Pty. Limited, Bondi Junction, Australia (non-U.S. corporation)  
PI US 5668116 19970916  
AI US 1996-613535 19960311 (8)  
RLI Continuation of Ser. No. US 1994-182541, filed on 18 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-71277, filed on 4 Jun 1993, now abandoned which is a division of Ser. No. US 1992-903081, filed on 10 Jun 1992, now patented, Pat. No. US 5470840 which is a division of Ser. No. US 1989-423455, filed on 19 Sep 1989, now patented, Pat. No. US 5145841

PRAI AU 1987-10951 19870319  
AU 1987-12478 19870615  
AU 1987-915819 19871209

DT Utility  
FS Granted  
EXNAM Primary Examiner: Peselev, Elli  
LREP Nixon & Vanderhye  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Figure(s); 21 Drawing Page(s)  
LN.CNT 1492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **method** for inactivating viruses which comprises the step of contacting the virus with an effective amount of a substantially pure divalent metal ion chelate of a polysulfate of xylan having glycosidically linked D-glucuronyl side chains with divalent metal ions chelated thereto wherein substantially all monovalent ions have been substituted by divalent metal ions, said divalent metal ions being

selected from the group consisting of Ca.sup.2+, Mg.sup.2+, Cu.sup.2+ and Zn.sup.2+.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 33 OF 37 USPATFULL  
AN 95:105830 USPATFULL  
TI Anti-inflammatory compounds and compositions  
IN Cullis-Hill, David, Bondi Junction, Australia  
Ghosh, Peter, Fairlight, Australia  
PA Arthropharm Pty Limited, Bondi Junction, Australia (non-U.S. corporation)  
PI US 5470840 19951128  
AI US 1992-903081 19920610 (7)  
RLI Division of Ser. No. US 1989-423455, filed on 19 Sep 1989, now patented, Pat. No. US 5145841  
PRAI AU 1987-951 19870319  
AU 1987-2478 19870615  
AU 1987-5819 19871209  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Peselev, Elli  
LREP Nixon & Vanderhye  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1,7  
DRWN 24 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 1338  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Multivalent metal ion complexes of a polysulfate of xylan having glycosidically linked D-glucuronyl side chains or derivatives thereof are provided, together with therapeutic compositions thereof having anti-inflammatory activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 34 OF 37 USPATFULL  
AN 93:18234 USPATFULL  
TI Hydrogel bead intervertebral disc nucleus  
IN Bao, Qi-Bin, Livingston, NJ, United States  
Higham, Paul A., Ringwood, NJ, United States  
PA Pfizer Hospital Products Group, Inc., New York, NY, United States (U.S. corporation)  
PI US 5192326 19930309  
AI US 1991-756957 19910909 (7)  
RLI Continuation-in-part of Ser. No. US 1990-633711, filed on 21 Dec 1990, now patented, Pat. No. US 5047055  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Frinks, Ronald  
LREP Richardson, Peter C., Akers, Lawrence C., Augustin, Raymond W.  
CLMN Number of Claims: 26  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Figure(s); 8 Drawing Page(s)  
LN.CNT 987  
AB A prosthetic nucleus for implantation in the disc space after removal of a damaged or degenerated nucleus is formed from a multiplicity of hydrogel beads having a water content of at least 30%. The beads are covered by a semi-permeable membrane. The membrane has porosity less than the size of the beads to thereby retain the beads therein but permit fluids to flow in and out of the prosthetic nucleus.

L12 ANSWER 35 OF 37 USPATFULL

AN 92:74607 USPATFULL  
TI Anti-inflammatory compounds and compositions  
IN Cullis-Hill, David, Bondi Junction, Australia  
Ghosh, Peter, Fairlight, Australia  
PA Arthropharm PTY. Limited, NSW, Australia (non-U.S. corporation)  
PI US 5145841 19920908  
WO 8807060 19880922  
AI US 1989-423455 19890919 (7)  
WO 1988-AU77 19880321  
19890919 PCT 371 date  
19890919 PCT 102(e) date  
PRAI AU 1987-951 19870319  
AU 1987-2478 19870615  
AU 1987-5819 19871209  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Griffin, Ronald W.; Assistant Examiner: Carson, Nancy S.  
LREP Nixon & Vanderhye  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 1269  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB **Method for the treatment of arthritis,**  
rheumatism and inflammation of connective tissue in which a multivalent metal ion substantially pure complex of xylan polysulphate, wherein the multivalent metal ion is selected from the group consisting of Ca.<sup>2+</sup>, Mg.<sup>2+</sup>, Cu.<sup>2+</sup> and Zn.<sup>2+</sup> is administered to a patient in need of such **treatment**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 36 OF 37 USPATFULL  
AN 91:73015 USPATFULL  
TI Hydrogel intervertebral disc nucleus  
IN Bao, Qi-Bin, Livingston, NJ, United States  
Higham, Paul A., Ringwood, NJ, United States  
PA Pfizer Hospital Products Group, Inc., New York, NY, United States (U.S. corporation)  
PI US 5047055 19910910  
AI US 1990-633711 19901221 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Frinks, Ronald  
LREP Richardson, Peter C., Akers, Lawrence C., Augustin, Raymond W.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 575  
AB A prosthetic nucleus for a vertebral disc is made of a hydrogel material. The hydrogel prosthetic nucleus has a shape generally conforming to the natural nucleus pulposus. The hydrogel has a water content of at least 30% and has a compressive strength of 4MNm.<sup>-2</sup> or greater. When the hydrogel material is dehydrated, it has a dimension of less than half of that of the hydrated hydrogel nucleus. The prosthetic nucleus may be formed of two or more pieces of hydrogel material which pieces, when combined, have a shape generally conforming to the natural nucleus.

L12 ANSWER 37 OF 37 USPATFULL  
AN 91:3080 USPATFULL  
TI Viscoelastic fluid for use in surgery and other therapies and

IN **method of using same**  
Pennell, Phillip E., Denver, CO, United States  
Blackmore, John M., Redwood City, CA, United States  
Allen, Mark D., Lakewood, CO, United States  
PA MDR Group, Inc., Golden, CO, United States (U.S. corporation)  
PI US 4983585 19910108  
AI US 1988-266684 19881103 (7)  
RLI Continuation-in-part of Ser. No. US 1987-45326, filed on 4 May 1987, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Friedman, Stanley J.; Assistant Examiner: Fay, Zohreh A.  
LREP Fliesler, Dubb, Meyer & Lovejoy  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 671

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to an improved viscoelastic fluid or gel for use in surgery and other therapies which consists of polyethylene oxide in selected concentrations not to exceed approximately 15% (15,000 ppm), contained in a physiologic balanced salt solution. The PEO may also be used in conjunction with viscosity enhancers which also act as heat stabilizers such as methyl cellulose and its derivatives, polyvinyl pyrrolidone or polyvinyl, alcohol or in conjunction with elasticizers such as low molecular weight polyethylene glycols or polypropylene glycols or in conjunction with gelation modifiers. These mixtures may be modified to increase retention time in the body by crosslinking with the use of materials like dimethylol urea. The invention encompasses the novel **method** of protecting and lubricating the corneal tissues during surgery with uses of different concentrations of the same solution introduced simultaneously to protect the inner cornea while periodically irrigating the outer cornea, all without obscuring the surgeon's view of the site. This invention also prevents the development of wound adhesion and has many utilizations in orthopedics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 11:16:39 ON 20 MAR 2003)  
FILE 'REGISTRY' ENTERED AT 11:16:58 ON 20 MAR 2003  
L1 1 S 123352-36-3  
FILE 'HCAPLUS' ENTERED AT 11:17:23 ON 20 MAR 2003  
L2 0 S L1 AND (OSTEOARTHRI? OR ARTHRIT?)  
L3 0 S L1 AND CARTILAGE  
FILE 'REGISTRY' ENTERED AT 11:19:02 ON 20 MAR 2003  
L4 1 S 123352-36-3/RN  
FILE 'MSDS-OHS' ENTERED AT 11:19:04 ON 20 MAR 2003  
SET NOTICE 1 DISPLAY  
SET LIN 80  
L5 0 S L4 AND 1/RN.CNT  
SET NOTICE LOGIN DISPLAY  
FILE 'REGISTRY' ENTERED AT 11:20:09 ON 20 MAR 2003  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'HCAPLUS' ENTERED AT 11:21:58 ON 20 MAR 2003

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPINDEX, WTEXTILES' ENTERED AT 11:22:15 ON 20 MAR 2003

L6 225795 S ARTHRITI?  
L7 4097 S L6 AND OSTEOT  
L8 1349 S L7 AND CARTILAGE  
L9 353 S L8 AND (COMPOS? OR COMPOUN?)  
L10 79 S L9 AND (HYALURON? OR CHONDROITIN)  
L11 67 S L10 AND (TREAT? OR METHOD)  
L12 37 S L11 AND DEGENER?  
L13 0 S L9 AND VISCOAT

=> file medline  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 136.31 150.51  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE -0.65 -0.65

FILE 'MEDLINE' ENTERED AT 11:30:14 ON 20 MAR 2003

FILE LAST UPDATED: 19 MAR 2003 (20030319/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/summ2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12  
97364 ARTHRITI?  
1961 OSTEOT  
42954 CARTILAGE  
3876 CARTILAGES  
44464 CARTILAGE  
(CARTILAGE OR CARTILAGES)  
227390 COMPOS?  
379385 COMPOUN?  
16022 HYALURON?  
10256 CHONDROITIN  
34 CHONDROITINS  
10264 CHONDROITIN  
(CHONDROITIN OR CHONDROITINS)  
1845426 TREAT?  
682389 METHOD  
1786459 METHODS  
2189467 METHOD  
(METHOD OR METHODS)  
90198 DEGENER?  
L14 0 L11 AND DEGENER?

=> file biosis  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.38 150.89  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.65

FILE 'BIOSIS' ENTERED AT 11:30:43 ON 20 MAR 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 19 March 2003 (20030319/ED)

```
=> s 112
    75333 ARTHRITI?
    12984 OSTEO
    28323 CARTILAGE
    1598 CARTILAGES
    28898 CARTILAGE
        (CARTILAGE OR CARTILAGES)
    452403 COMPOS?
    339585 COMPOUN?
    14904 HYALURON?
    9358 CHONDROITIN
    43 CHONDROITINS
    9372 CHONDROITIN
        (CHONDROITIN OR CHONDROITINS)
    1604529 TREAT?
    2064108 METHOD
    2081214 METHODS
    2738532 METHOD
        (METHOD OR METHODS)
    80397 DEGENER?
L15      0 L11 AND DEGENER?
```

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.84	151.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.65

FILE 'EMBASE' ENTERED AT 11:31:09 ON 20 MAR 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 13 Mar 2003 (20030313/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

```
=> s 112
    82018 ARTHRITI?
    1584 OSTEO
    38360 CARTILAGE
    1885 CARTILAGES
    38902 CARTILAGE
        (CARTILAGE OR CARTILAGES)
    196648 COMPOS?
    1501118 COMPOUN?
    13907 HYALURON?
```

7928 CHONDROITIN  
29 CHONDROITINS  
7937 CHONDROITIN  
(CHONDROITIN OR CHONDROITINS)  
1740207 TREAT?  
566888 METHOD  
642116 METHODS  
1098605 METHOD  
(METHOD OR METHODS)  
88101 DEGENER?  
L16 0 L11 AND DEGENER?  
  
=> dis hist  
  
(FILE 'HOME' ENTERED AT 11:16:39 ON 20 MAR 2003)  
  
FILE 'REGISTRY' ENTERED AT 11:16:58 ON 20 MAR 2003  
L1 1 S 123352-36-3  
  
FILE 'HCAPLUS' ENTERED AT 11:17:23 ON 20 MAR 2003  
L2 0 S L1 AND (OSTEOARTHRI? OR ARTHRIT?)  
L3 0 S L1 AND CARTILAGE  
  
FILE 'REGISTRY' ENTERED AT 11:19:02 ON 20 MAR 2003  
L4 1 S 123352-36-3/RN  
  
FILE 'MSDS-OHS' ENTERED AT 11:19:04 ON 20 MAR 2003  
SET NOTICE 1 DISPLAY  
SET LIN 80  
L5 0 S L4 AND 1/RN.CNT  
SET NOTICE LOGIN DISPLAY  
  
FILE 'REGISTRY' ENTERED AT 11:20:09 ON 20 MAR 2003  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY  
  
FILE 'HCAPLUS' ENTERED AT 11:21:58 ON 20 MAR 2003  
  
FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,  
PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,  
USPAT2, WPINDEX, WTEXTILES' ENTERED AT 11:22:15 ON 20 MAR 2003  
L6 225795 S ARTHRITI?  
L7 4097 S L6 AND OSTEO  
L8 1349 S L7 AND CARTILAGE  
L9 353 S L8 AND (COMPOS? OR COMPOUN?)  
L10 79 S L9 AND (HYALURON? OR CHONDROITIN)  
L11 67 S L10 AND (TREAT? OR METHOD)  
L12 37 S L11 AND DEGENER?  
L13 0 S L9 AND VISCOAT  
  
FILE 'MEDLINE' ENTERED AT 11:30:14 ON 20 MAR 2003  
L14 0 S L12  
  
FILE 'BIOSIS' ENTERED AT 11:30:43 ON 20 MAR 2003  
L15 0 S L12  
  
FILE 'EMBASE' ENTERED AT 11:31:09 ON 20 MAR 2003  
L16 0 S L12